PrimeGen US Enters Merger Agreement with DT Cloud Star, Valued at Approximately $1.5B
PrimeGen US, a pioneering biotech company advancing innovative stem cell and exosome therapies, announced it has entered into a definitive business combination agreement dated as of February 2, with DT Cloud Star Acquisition Corporation, a publicly traded special purpose acquisition company. The transaction implies an equity value for PrimeGen US of approximately $1.5B and is expected to provide access to the public markets capital, which the combined company intends to use to advance clinical development, regulatory activities, and if approved, potential commercialization of its lead programs. Upon closing the combined company is expected to operate as PrimeGen US and is anticipated to list on the Nasdaq, subject to Nasdaq approval, under a new ticker symbol. The transaction is currently expected to close in the second half of 2026, although there can be no assurance regarding the timing or completion of the transaction. A.G.P./Alliance Global Partners is serving as the financial advisor to PrimeGen US, Sichenzia Ross Ference Carmel LLP, is serving as the legal advisor to PrimeGen US. PrimeGen US is supported by special counsel Steven C. Schinko of Schinko Law, a boutique practice providing sophisticated corporate, transactional, and strategic counsel to emerging growth companies and high-net-worth individuals. Loeb & Loeb is serving as the legal advisor to DT Cloud Star.
Trade with 70% Backtested Accuracy
Analyst Views on DTSQ
About DTSQ
About the author
PrimeGen to Merge with DT Cloud Star at $1.5 Billion Valuation
- Merger Overview: PrimeGen is set to merge with DT Cloud Star Acquisition Corporation (Nasdaq: DTSQ) in a deal valued at approximately $1.5 billion, with a closing targeted for H2 2026, marking a significant milestone for PrimeGen in the regenerative medicine sector.
- Funding Utilization: The merger aims to provide funding for PrimeGen's clinical trials, regulatory efforts, and potential commercialization of its regenerative medicine programs, particularly treatments for acute liver failure using its Triple Activated MSC platform.
- Technological Innovation: PrimeGen focuses on developing Triple Activated Mesenchymal Stem Cells as a novel cell-based treatment for acute liver injury and related critical conditions, showcasing its innovative potential in the regenerative medicine field.
- Market Outlook: By merging with DT Cloud Star, PrimeGen not only secures essential funding but also enhances its competitive position in the regenerative medicine market, facilitating the clinical application and commercialization of its treatment solutions.
PrimeGen to Merge with DT Cloud Star at $1.5 Billion Valuation
- Merger Overview: PrimeGen is set to merge with DT Cloud Star Acquisition Corporation (Nasdaq: DTSQ) in a deal valued at approximately $1.5 billion, with a closing targeted for H2 2026, marking a significant milestone for PrimeGen in the regenerative medicine sector.
- Funding Utilization: The merger aims to provide funding for PrimeGen's clinical trials, regulatory efforts, and potential commercialization of its regenerative medicine programs, particularly treatments for acute liver failure using its Triple Activated MSC platform.
- Technological Innovation: PrimeGen focuses on developing Triple Activated Mesenchymal Stem Cells as a novel cell-based treatment for acute liver injury and related critical conditions, showcasing its innovative potential in the regenerative medicine field.
- Market Outlook: By merging with DT Cloud Star, PrimeGen not only secures essential funding but also enhances its competitive position in the regenerative medicine market, facilitating the clinical application and commercialization of its treatment solutions.
